Conferences - Results from #40

Viewing 41-60 of 11872 articles

SUO 2024: Moonrise-1: Phase 3 Study of TAR-210, an Erdafitinib Intravesical Targeted Releasing System, Versus Intravesical Chemotherapy in Patients with FGFR-Altered Intermediate Risk Non Muscle Invasive Bladder Cancer

SUO 2024: Long-Term Outcomes of Primary Chemoablation of Low-Grade UTUC with UGN-101, a Mitomycin Reverse Thermal Gel

SUO 2024: Initial Results of a Multicenter Phase II trial of Intravesical Gemcitabine plus BCG for Patients with BCG-exposed Non-muscle Invasive Bladder Cancer

SUO 2024: Urine Tumor DNA Analysis in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) Patients Treated with Durvalumab Containing Regimens in the HCRN GU16-243: ADAPT-BLADDER Trial.

SUO 2024: Risk Stratification AI-Driven Digital Biomarkers

SUO 2024: Adjuvant Chemotherapy after Primary RPLND for Seminoma - When, Who, if Ever?

SUO 2024: Utility of Rescue Bacillus Calmette-Guerin Therapy in Treatment of BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer

SUO 2024: Home Instillation of UGN-102 for Primary Chemoablation of Recurrent Low-Grade Intermediate Risk NMIBC: A Single Arm, Open Label, Phase 3B Trial

SUO 2024: Classification of Adverse Events after Prostate Cancer Hydrogel Perirectal Spacer Insertion Using Large Language Models

SUO 2024: MK-5684-003: A Phase 3 Study of CYP11A1 Inhibitor Opevesostat Versus Next-Generation Hormonal Agent (NHA) Switch in Metastatic Castration-Resistant Prostate Cancer After NHA and Taxane-Based Chemotherapy

SUO 2024: Phase 1B/2 Study of Combination 177Lu Girentuximab + Cabozantinib and Nivolumab in Treatment Naïve Patients with Advanced Clear Cell RCC

SUO 2024: PIVOT-006: A Phase 3, Randomized Study of Adjuvant Intravesical Cretostimogene Grenadenorepvec versus Surveillance for the Treatment of Intermediate-Risk Non-Muscle Invasive Bladder Cancer

SUO 2024: Primary Chemoablation of Recurrent Low-Grade Intermediate Risk NMIBC with UGN-102: A Single Arm, Open Label, Phase 3 Trial (ENVISION)

SUO 2024: Safety and Tolerability of TAR-200 Monotherapy in Patients with BCG-Unresponsive High Risk NMIBC in SunRISE-1

SUO 2024: BOND-003 Cohort P: A Multi-national, Single-arm Study of Intravesical Cretostimogene Grenadenorepvec for the Treatment of High-Risk, Papillary Only, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

SUO 2024: UR001: A Phase 1 Dose-Escalation Study of UGN-301 (Zalifrelimab) in Patients with Recurrent Non Muscle Invasive Bladder Cancer

SUO 2024: AI Concept in Prostate Cancer: Remote Surgery

SUO 2024: Testosterone Supplementation After Treatment for Localized Prostate Cancer

SUO 2024: Low-grade and High-grade Intermediate-risk Non-muscle Invasive Bladder Cancers Respond Differently to Bacillus Calmette-Guerin and Gemcitabine-Docetaxal

SUO 2024: SunRISe-5: A Phase III, Randomized, Open-label Study of TAR-200 Compared with Intravesical Chemotherapy After Bacillus Calmette-Guerin in Recurrent, High-risk, Non-muscle Invasive Bladder Cancer

1
2
3
4
5
6
7
8
9
10